Immune Checkpoint-Induced Colitis: A Single-Center Retrospective Cohort Study
Journal of Clinical Medicine · 13.10.2025 · 14 (20) · 7219
DOI: 10.3390/jcm14207219 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Clinical Medicine, online erschienen am 13.10.2025. Verfasst von Bengt Van Holder und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Ghent University Hospital, 9000 Ghent, Belgium. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are often complicated by immune-related adverse events, particularly colitis. With increasing ICI use, understanding the clinical course and management of ICI-induced colitis is essential.
Objectives
To characterize the clinical, endoscopic, and histological features of ICI-induced colitis and evaluate treatment outcomes, focusing on the use of corticosteroids and second-line biologicals (infliximab and vedolizumab) in a real-world setting.
Methods
A retrospective cohort study was conducted at Ghent University Hospital, including 77 adult patients diagnosed with ICI-induced colitis in between 2012 and 2023. Clinical, biochemical, endoscopic, and histological data were analyzed, along with treatment response and safety outcomes.
Results
Patients with ICI-induced colitis received anti-PD-1/PD-L1 (64.9%), anti-CTLA-4 (9.1%), or combination of both (26.0%). In patients with normal endoscopic findings, histological signs of colitis were observed in 88.0%. Combination ICI therapy was associated with higher Mayo scores (p = 0.029) and increased need for biologicals (p = 0.011) compared to anti-PD-1/PD-L1 monotherapy. Clinical response rates were 79.6% with corticosteroids and 100.0% with biologicals. Rechallenge with ICIs lead to a 17.4% relapse rate. No colitis-related deaths were observed.
Conclusions
In this retrospective study, we demonstrate that random colon biopsies reveal microscopic ICI-induced colitis in most patients with absence of endoscopic disease. Combination ICI therapy predicts a corticosteroid-refractory course, supporting the need for early escalation to biologicals. ICI rechallenge appears feasible, as relapse rates were relatively low and colitis morbidity remained manageable. Prospective studies are needed to refine therapeutic strategies and improve patient outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Ghent University Hospital, 9000 Ghent, Belgium.
- Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium.
- Department of Gastroenterology and Hepatology, Ghent University Hospital, 9000 Ghent, Belgium.
- Department of Pathology, Ghent University Hospital, 9000 Ghent, Belgium.
- Respiratory Medicine, Ghent University Hospital, 9000 Ghent, Belgium.
ORCID-Profile: Triana Lobatón, Anne Hoorens, Jeroen Geldof, Celine Jacobs, Eline Naert, Michael Saerens
Zitieren
APA
Van Holder, B., Vereecke, J., Ureel, N., Lobatón, T., Hoorens, A., Lievens, A., Truyens, M., Rottey, S., Vermaelen, K., D'Cruz, V., Geldof, J., Jacobs, C., Naert, E., De Mulder, E., & Saerens, M. (2025). Immune Checkpoint-Induced Colitis: A Single-Center Retrospective Cohort Study. Journal of Clinical Medicine, 14(20), 7219. https://doi.org/10.3390/jcm14207219
Vancouver
Van Holder B, Vereecke J, Ureel N, Lobatón T, Hoorens A, Lievens A, et al. Immune Checkpoint-Induced Colitis: A Single-Center Retrospective Cohort Study. Journal of Clinical Medicine. 2025;14(20):7219. doi:10.3390/jcm14207219
BibTeX
@article{VanHolder2025,
author = {Van Holder, Bengt and Vereecke, Julie and Ureel, Nathan and Lobatón, Triana and Hoorens, Anne and Lievens, Amber and Truyens, Marie and Rottey, Sylvie and Vermaelen, Karim and D'Cruz, Venita and Geldof, Jeroen and Jacobs, Celine and Naert, Eline and De Mulder, Elien and Saerens, Michael},
title = {Immune Checkpoint-Induced Colitis: A Single-Center Retrospective Cohort Study},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {20},
pages = {7219},
doi = {10.3390/jcm14207219}
}
EUVIMED